3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
61
Terminated
19
Recruiting
14
Active not recruiting
12
Withdrawn
3
Not yet recruiting
3
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
5
Genitourinary
2
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
1
Leukemia, Plasma Cell
1
Interventions
Cytarabine
102
Cyclophosphamide
74
fludarabine
45
Idarubicin
39
Decitabine
36
Etoposide
35
Azacitidine
34
Methotrexate
31
Daunorubicin
30
Vincristine
28
Dexamethasone
27
venetoclax
25
Busulfan
24
Imatinib Mesylate
23
Radiotherapy
20
Mercaptopurine
20
Granulocyte Colony-Stimulating Factor
20
Dasatinib
19
Peripheral Blood Stem Cell Transplantation
18
Mitoxantrone
17
Doxorubicin
17
Immunotherapy, Adoptive
16
Rituximab
15
Asparaginase
15
Tretinoin
14
Cladribine
14
fludarabine phosphate
13
Prednisone
13
Prednisolone
13
Melphalan
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Calcium Dobesilate
×
Other hematologic neoplasm
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled